Scotland’s SMC OKs Drugs For Cancer & Plaque Psoriasis
But the HTA body has rejected two other anticancer medicines
Executive Summary
The Scottish Medicines Consortium has OKd Keytruda, Decapeptyl, Yescarta and Skyrizi after patient access schemes were agreed that improved their cost-effectiveness. But Perjeta and Xtandi were rejected because the companies made no solid economic case for NHS funding.
You may also be interested in...
Scottish HTA Reverses No For Yescarta
The Scottish health technology appraisal body, the SMC, has okayed Gilead’s CAR-T therapy Yescarta for use on the Scottish National Health Service.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.